Mitochondria “fuel” breast cancer metabolism: Fifteen markers of mitochondrial biogenesis label epithelial cancer cells, but are excluded from adjacent stromal cells

References

• Martinez-Outschoorn UE, Pestell RG, Howell A, Tykocinski ML, Nagajyothi F, Machado FS, et al. Energy transfer in “parasitic” cancer metabolism: mitochondria are the powerhouse and Achilles’ heel of tumor cells. Cell Cycle 2011; 10:4208 - 16; http://dx.doi.org/10.4161/cc.10.24.18487; PMID: 22033146
   PubMed Web of Science ®Google Scholar
• Martinez-Outschoorn UE, Sotgia F, Lisanti MP. Power surge: supporting cells “fuel” cancer cell mitochondria. Cell Metab 2012; 15:4 - 5; http://dx.doi.org/10.1016/j.cmet.2011.12.011; PMID: 22225869
   PubMed Web of Science ®Google Scholar
• Wallace DC. Mitochondria and cancer. Nat Rev Cancer 2012; 12:685 - 98; http://dx.doi.org/10.1038/nrc3365; PMID: 23001348
   PubMed Web of Science ®Google Scholar
• Pavlides S, Vera I, Gandara R, Sneddon S, Pestell RG, Mercier I, et al. Warburg meets autophagy: cancer-associated fibroblasts accelerate tumor growth and metastasis via oxidative stress, mitophagy, and aerobic glycolysis. Antioxid Redox Signal 2012; 16:1264 - 84; http://dx.doi.org/10.1089/ars.2011.4243; PMID: 21883043
   PubMed Web of Science ®Google Scholar
• Pavlides S, Whitaker-Menezes D, Castello-Cros R, Flomenberg N, Witkiewicz AK, Frank PG, et al. The reverse Warburg effect: aerobic glycolysis in cancer associated fibroblasts and the tumor stroma. Cell Cycle 2009; 8:3984 - 4001; http://dx.doi.org/10.4161/cc.8.23.10238; PMID: 19923890
   PubMed Web of Science ®Google Scholar
• Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N, Birbe RC, Witkiewicz AK, Howell A, et al. Hyperactivation of oxidative mitochondrial metabolism in epithelial cancer cells in situ: visualizing the therapeutic effects of metformin in tumor tissue. Cell Cycle 2011; 10:4047 - 64; http://dx.doi.org/10.4161/cc.10.23.18151; PMID: 22134189
   PubMed Web of Science ®Google Scholar
• Whitaker-Menezes D, Martinez-Outschoorn UE, Lin Z, Ertel A, Flomenberg N, Witkiewicz AK, et al. Evidence for a stromal-epithelial “lactate shuttle” in human tumors: MCT4 is a marker of oxidative stress in cancer-associated fibroblasts. Cell Cycle 2011; 10:1772 - 83; http://dx.doi.org/10.4161/cc.10.11.15659; PMID: 21558814
   PubMed Web of Science ®Google Scholar
• Sotgia F, Martinez-Outschoorn UE, Howell A, Pestell RG, Pavlides S, Lisanti MP. Caveolin-1 and cancer metabolism in the tumor microenvironment: markers, models, and mechanisms. Annu Rev Pathol 2012; 7:423 - 67; http://dx.doi.org/10.1146/annurev-pathol-011811-120856; PMID: 22077552
   PubMed Web of Science ®Google Scholar
• Sotgia F, Martinez-Outschoorn UE, Lisanti MP. Mitochondrial oxidative stress drives tumor progression and metastasis: should we use antioxidants as a key component of cancer treatment and prevention?. BMC Med 2011; 9:62; http://dx.doi.org/10.1186/1741-7015-9-62; PMID: 21605374
   PubMed Web of Science ®Google Scholar
• Sotgia F, Martinez-Outschoorn UE, Pavlides S, Howell A, Pestell RG, Lisanti MP. Understanding the Warburg effect and the prognostic value of stromal caveolin-1 as a marker of a lethal tumor microenvironment. Breast Cancer Res 2011; 13:213; http://dx.doi.org/10.1186/bcr2892; PMID: 21867571
   PubMed Web of Science ®Google Scholar
• Sotgia F, Whitaker-Menezes D, Martinez-Outschoorn UE, Flomenberg N, Birbe RC, Witkiewicz AK, et al. Mitochondrial metabolism in cancer metastasis: visualizing tumor cell mitochondria and the “reverse Warburg effect” in positive lymph node tissue. Cell Cycle 2012; 11:1445 - 54; http://dx.doi.org/10.4161/cc.19841; PMID: 22395432
   PubMed Web of Science ®Google Scholar
• Migneco G, Whitaker-Menezes D, Chiavarina B, Castello-Cros R, Pavlides S, Pestell RG, et al. Glycolytic cancer associated fibroblasts promote breast cancer tumor growth, without a measurable increase in angiogenesis: evidence for stromal-epithelial metabolic coupling. Cell Cycle 2010; 9:2412 - 22; http://dx.doi.org/10.4161/cc.9.12.11989; PMID: 20562527
   PubMed Web of Science ®Google Scholar
• Balliet RM, Capparelli C, Guido C, Pestell TG, Martinez-Outschoorn UE, Lin Z, et al. Mitochondrial oxidative stress in cancer-associated fibroblasts drives lactate production, promoting breast cancer tumor growth: understanding the aging and cancer connection. Cell Cycle 2011; 10:4065 - 73; http://dx.doi.org/10.4161/cc.10.23.18254; PMID: 22129993
   PubMed Web of Science ®Google Scholar
• Chiavarina B, Whitaker-Menezes D, Martinez-Outschoorn UE, Witkiewicz AK, Birbe RC, Howell A, et al. Pyruvate kinase expression (PKM1 and PKM2) in cancer-associated fibroblasts drives stromal nutrient production and tumor growth. Cancer Biol Ther 2011; 12:12; PMID: 22236875
   PubMed Web of Science ®Google Scholar
• Chiavarina B, Whitaker-Menezes D, Migneco G, Martinez-Outschoorn UE, Pavlides S, Howell A, et al. HIF1-alpha functions as a tumor promoter in cancer associated fibroblasts, and as a tumor suppressor in breast cancer cells: Autophagy drives compartment-specific oncogenesis. Cell Cycle 2010; 9:3534 - 51; http://dx.doi.org/10.4161/cc.9.17.12908; PMID: 20864819
   PubMed Web of Science ®Google Scholar
• Capparelli C, Guido C, Whitaker-Menezes D, Bonuccelli G, Balliet R, Pestell TG, et al. Autophagy and senescence in cancer-associated fibroblasts metabolically supports tumor growth and metastasis via glycolysis and ketone production. Cell Cycle 2012; 11:2285 - 302; http://dx.doi.org/10.4161/cc.20718; PMID: 22684298
   PubMed Web of Science ®Google Scholar
• Capparelli C, Whitaker-Menezes D, Guido C, Balliet R, Pestell TG, Howell A, et al. CTGF drives autophagy, glycolysis and senescence in cancer-associated fibroblasts via HIF1 activation, metabolically promoting tumor growth. Cell Cycle 2012; 11:2272 - 84; http://dx.doi.org/10.4161/cc.20717; PMID: 22684333
   PubMed Web of Science ®Google Scholar
• Guido C, Whitaker-Menezes D, Capparelli C, Balliet R, Lin Z, Pestell RG, et al. Metabolic reprogramming of cancer-associated fibroblasts by TGF-β drives tumor growth: connecting TGF-β signaling with “Warburg-like” cancer metabolism and L-lactate production. Cell Cycle 2012; 11:3019 - 35; http://dx.doi.org/10.4161/cc.21384; PMID: 22874531
   PubMed Web of Science ®Google Scholar
• Guido C, Whitaker-Menezes D, Lin Z, Pestell RG, Howell A, Zimmers TA, et al. Mitochondrial fission induces glycolytic reprogramming in cancer-associated myofibroblasts, driving stromal lactate production, and early tumor growth. Oncotarget 2012; 3:798 - 810; PMID: 22878233
   PubMed Web of Science ®Google Scholar
• Carito V, Bonuccelli G, Martinez-Outschoorn UE, Whitaker-Menezes D, Caroleo MC, Cione E, et al. Metabolic remodeling of the tumor microenvironment: Migration stimulating factor (MSF) reprograms myofibroblasts toward lactate production, fueling anabolic tumor growth. Cell Cycle 2012; 11:3403 - 14; http://dx.doi.org/10.4161/cc.21701; PMID: 22918248
   PubMed Web of Science ®Google Scholar
• Chiavarina B, Martinez-Outschoorn UE, Whitaker-Menezes D, Howell A, Tanowitz HB, Pestell RG, et al. Metabolic reprogramming and two-compartment tumor metabolism: opposing role(s) of HIF1α and HIF2α in tumor-associated fibroblasts and human breast cancer cells. Cell Cycle 2012; 11:3280 - 9; http://dx.doi.org/10.4161/cc.21643; PMID: 22894905
   PubMed Web of Science ®Google Scholar
• Capparelli C, Chiavarina B, Whitaker-Menezes D, Pestell TG, Pestell RG, Hulit J, et al. CDK inhibitors (p16/p19/p21) induce senescence and autophagy in cancer-associated fibroblasts, “fueling” tumor growth via paracrine interactions, without an increase in neo-angiogenesis. Cell Cycle 2012; 11:3599 - 610; http://dx.doi.org/10.4161/cc.21884; PMID: 22935696
   PubMed Web of Science ®Google Scholar
• Salem AF, Whitaker-Menezes D, Lin Z, Martinez-Outschoorn UE, Tanowitz HB, Al-Zoubi MS, et al. Two-compartment tumor metabolism: autophagy in the tumor microenvironment and oxidative mitochondrial metabolism (OXPHOS) in cancer cells. Cell Cycle 2012; 11:2545 - 56; http://dx.doi.org/10.4161/cc.20920; PMID: 22722266
   PubMed Web of Science ®Google Scholar
• Salem AF, Howell A, Sartini M, Sotgia F, Lisanti MP. Downregulation of stromal BRCA1 drives breast cancer tumor growth via upregulation of HIF-1alpha, autophagy and ketone body production. Cell Cycle 2012; 11:4167 - 73; PMID: 22157090
   PubMed Web of Science ®Google Scholar
• Salem AF, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP. Mitochondrial biogenesis in epithelial cancer cells promotes breast cancer tumor growth and confers autophagy resistance. Cell Cycle 2012; 11:4174 - 80; PMID: 22157090
   PubMed Web of Science ®Google Scholar
• Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, Howell A, Lisanti MP, Sotgia F. Ketone bodies and two-compartment tumor metabolism: Stromal ketone production fuels mitochondrial biogenesis in epithelial cancer cells. Cell Cycle 2012; 11:3956 - 63; PMID: 22157090
   PubMed Web of Science ®Google Scholar
• Martinez-Outschoorn UE, Lin Z, Whitaker-Menezes D, Howell A, Sotgia F, Lisanti MP. Ketone body utilization drives tumor growth and metastasis. Cell Cycle 2012; 11:3964 - 71; PMID: 22157090
   PubMed Web of Science ®Google Scholar
• Ertel A, Tsirigos A, Whitaker-Menezes D, Birbe RC, Pavlides S, Martinez-Outschoorn UE, et al. Is cancer a metabolic rebellion against host aging? In the quest for immortality, tumor cells try to save themselves by boosting mitochondrial metabolism. Cell Cycle 2012; 11:253 - 63; http://dx.doi.org/10.4161/cc.11.2.19006; PMID: 22234241
   PubMed Web of Science ®Google Scholar
• Witkiewicz AK, Dasgupta A, Sammons S, Er O, Potoczek MB, Guiles F, et al. Loss of stromal caveolin-1 expression predicts poor clinical outcome in triple negative and basal-like breast cancers. Cancer Biol Ther 2010; 10:135 - 43; http://dx.doi.org/10.4161/cbt.10.2.11983; PMID: 20431349
   PubMed Web of Science ®Google Scholar
• Witkiewicz AK, Dasgupta A, Sotgia F, Mercier I, Pestell RG, Sabel M, et al. An absence of stromal caveolin-1 expression predicts early tumor recurrence and poor clinical outcome in human breast cancers. Am J Pathol 2009; 174:2023 - 34; http://dx.doi.org/10.2353/ajpath.2009.080873; PMID: 19411448
   PubMed Web of Science ®Google Scholar
• Witkiewicz AK, Whitaker-Menezes D, Dasgupta A, Philp NJ, Lin Z, Gandara R, et al. Using the “reverse Warburg effect” to identify high-risk breast cancer patients: stromal MCT4 predicts poor clinical outcome in triple-negative breast cancers. Cell Cycle 2012; 11:1108 - 17; http://dx.doi.org/10.4161/cc.11.6.19530; PMID: 22313602
   PubMed Web of Science ®Google Scholar
• Martinez-Outschoorn UE, Prisco M, Ertel A, Tsirigos A, Lin Z, Pavlides S, et al. Ketones and lactate increase cancer cell “stemness,” driving recurrence, metastasis and poor clinical outcome in breast cancer: achieving personalized medicine via Metabolo-Genomics. Cell Cycle 2011; 10:1271 - 86; http://dx.doi.org/10.4161/cc.10.8.15330; PMID: 21512313
   PubMed Web of Science ®Google Scholar
• Witkiewicz AK, Dasgupta A, Nguyen KH, Liu C, Kovatich AJ, Schwartz GF, et al. Stromal caveolin-1 levels predict early DCIS progression to invasive breast cancer. Cancer Biol Ther 2009; 8:1071 - 9; http://dx.doi.org/10.4161/cbt.8.11.8874; PMID: 19502809
   PubMed Web of Science ®Google Scholar
• Witkiewicz AK, Kline J, Queenan M, Brody JR, Tsirigos A, Bilal E, et al. Molecular profiling of a lethal tumor microenvironment, as defined by stromal caveolin-1 status in breast cancers. Cell Cycle 2011; 10:1794 - 809; http://dx.doi.org/10.4161/cc.10.11.15675; PMID: 21521946
   PubMed Web of Science ®Google Scholar
• Qian N, Ueno T, Kawaguchi-Sakita N, Kawashima M, Yoshida N, Mikami Y, et al. Prognostic significance of tumor/stromal caveolin-1 expression in breast cancer patients. Cancer Sci 2011; 102:1590 - 6; http://dx.doi.org/10.1111/j.1349-7006.2011.01985.x; PMID: 21585620
   PubMed Web of Science ®Google Scholar
• Simpkins SA, Hanby AM, Holliday DL, Speirs V. Clinical and functional significance of loss of caveolin-1 expression in breast cancer-associated fibroblasts. J Pathol 2012; 227:490 - 8; http://dx.doi.org/10.1002/path.4034; PMID: 22488553
   PubMed Web of Science ®Google Scholar
• Koo JS, Park S, Kim SI, Lee S, Park BW. The impact of caveolin protein expression in tumor stroma on prognosis of breast cancer. Tumour Biol 2011; 32:787 - 99; http://dx.doi.org/10.1007/s13277-011-0181-6; PMID: 21584795
   PubMed Web of Science ®Google Scholar
• El-Gendi SM, Mostafa MF, El-Gendi AM. Stromal caveolin-1 expression in breast carcinoma. Correlation with early tumor recurrence and clinical outcome. Pathol Oncol Res 2012; 18:459 - 69; http://dx.doi.org/10.1007/s12253-011-9469-5; PMID: 22057638
   PubMed Web of Science ®Google Scholar
• Sloan EK, Ciocca DR, Pouliot N, Natoli A, Restall C, Henderson MA, et al. Stromal cell expression of caveolin-1 predicts outcome in breast cancer. Am J Pathol 2009; 174:2035 - 43; http://dx.doi.org/10.2353/ajpath.2009.080924; PMID: 19411449
   PubMed Web of Science ®Google Scholar
• Di Vizio D, Morello M, Sotgia F, Pestell RG, Freeman MR, Lisanti MP. An absence of stromal caveolin-1 is associated with advanced prostate cancer, metastatic disease and epithelial Akt activation. Cell Cycle 2009; 8:2420 - 4; http://dx.doi.org/10.4161/cc.8.15.9116; PMID: 19556867
   PubMed Web of Science ®Google Scholar
• Wu KN, Queenan M, Brody JR, Potoczek M, Sotgia F, Lisanti MP, et al. Loss of stromal caveolin-1 expression in malignant melanoma metastases predicts poor survival. Cell Cycle 2011; 10:4250 - 5; http://dx.doi.org/10.4161/cc.10.24.18551; PMID: 22134245
   PubMed Web of Science ®Google Scholar
• Casey T, Bond J, Tighe S, Hunter T, Lintault L, Patel O, et al. Molecular signatures suggest a major role for stromal cells in development of invasive breast cancer. Breast Cancer Res Treat 2009; 114:47 - 62; http://dx.doi.org/10.1007/s10549-008-9982-8; PMID: 18373191
   PubMed Web of Science ®Google Scholar
• Xu X, Qiao M, Zhang Y, Jiang Y, Wei P, Yao J, et al. Quantitative proteomics study of breast cancer cell lines isolated from a single patient: discovery of TIMM17A as a marker for breast cancer. Proteomics 2010; 10:1374 - 90; http://dx.doi.org/10.1002/pmic.200900380; PMID: 20198662
   PubMed Web of Science ®Google Scholar
• Salhab M, Patani N, Jiang W, Mokbel K. High TIMM17A expression is associated with adverse pathological and clinical outcomes in human breast cancer. Breast Cancer 2012; 19:153 - 60; http://dx.doi.org/10.1007/s12282-010-0228-3; PMID: 20972741
   PubMed Web of Science ®Google Scholar
• Aleskandarany MA, Negm OH, Rakha EA, Ahmed MA, Nolan CC, Ball GR, et al. TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome. Breast Cancer Res Treat 2012; 136:419 - 27; http://dx.doi.org/10.1007/s10549-012-2249-4; PMID: 23053644
   PubMed Web of Science ®Google Scholar
• Schimmer AD, Skrtić M. Therapeutic potential of mitochondrial translation inhibition for treatment of acute myeloid leukemia. Expert Rev Hematol 2012; 5:117 - 9; http://dx.doi.org/10.1586/ehm.12.8; PMID: 22475277
   PubMed Web of Science ®Google Scholar
• Skrtić M, Sriskanthadevan S, Jhas B, Gebbia M, Wang X, Wang Z, et al. Inhibition of mitochondrial translation as a therapeutic strategy for human acute myeloid leukemia. Cancer Cell 2011; 20:674 - 88; http://dx.doi.org/10.1016/j.ccr.2011.10.015; PMID: 22094260
   PubMed Web of Science ®Google Scholar
• Järås M, Ebert BL. Power cut: inhibiting mitochondrial translation to target leukemia. Cancer Cell 2011; 20:555 - 6; http://dx.doi.org/10.1016/j.ccr.2011.10.028; PMID: 22094249
   PubMed Web of Science ®Google Scholar
• Wang JH, Chen XT, Wen ZS, Zheng M, Deng JM, Wang MZ, et al. High Expression of GOLPH3 in Esophageal Squamous Cell Carcinoma Correlates with Poor Prognosis. PLoS One 2012; 7:e45622; http://dx.doi.org/10.1371/journal.pone.0045622; PMID: 23056210
   PubMedGoogle Scholar
• Hua X, Yu L, Pan W, Huang X, Liao Z, Xian Q, et al. Increased expression of Golgi phosphoprotein-3 is associated with tumor aggressiveness and poor prognosis of prostate cancer. Diagn Pathol 2012; 7:127; http://dx.doi.org/10.1186/1746-1596-7-127; PMID: 23006319
   PubMed Web of Science ®Google Scholar
• Li H, Guo L, Chen SW, Zhao XH, Zhuang SM, Wang LP, et al. GOLPH3 overexpression correlates with tumor progression and poor prognosis in patients with clinically N0 oral tongue cancer. J Transl Med 2012; 10:168; http://dx.doi.org/10.1186/1479-5876-10-168; PMID: 22905766
   PubMed Web of Science ®Google Scholar
• Zhou J, Xu T, Qin R, Yan Y, Chen C, Chen Y, et al. Overexpression of Golgi phosphoprotein-3 (GOLPH3) in glioblastoma multiforme is associated with worse prognosis. J Neurooncol 2012; 110:195 - 203; http://dx.doi.org/10.1007/s11060-012-0970-9; PMID: 22972189
   PubMed Web of Science ®Google Scholar